{"filings":[{"id":1086438,"accession_number":"0001104659-26-074709","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2026-06-16T21:26:34+00:00","items":["5.07"],"status":"ready","headline":"Adagio Medical stockholders elect Orly Mishan and Sean Salmon as directors, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Orly Mishan elected with 11,930,745 votes for, 1,396,139 withheld; Sean Salmon elected with 13,322,425 for, 4,459 withheld.","Ratification of WithumSmith+Brown, PC as auditor for FY2026 approved: 16,055,195 for, 14,081 against, 708 abstain.","Quorum of 72.35% of outstanding shares (16,069,984 of 22,210,459) present or represented at the June 16, 2026 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1028316,"accession_number":"0001104659-26-073517","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2026-06-12T20:32:32+00:00","items":["3.01"],"status":"ready","headline":"Adagio Medical receives Nasdaq notice for bid price < $1; 180-day cure period until Dec 9, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice from Nasdaq on June 12, 2026 for non-compliance with Listing Rule 5550(a)(2) (min $1 bid).","Stock continues trading on Nasdaq Capital Market during 180-day cure period ending Dec 9, 2026.","To regain compliance, bid price must close at or above $1 for at least 10 consecutive trading days.","Second 180-day period may be available if necessary; delisting possible if non-compliance persists.","Company considering options including reverse stock split to meet bid price requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":582796,"accession_number":"0001104659-26-065180","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2026-05-21T20:31:34+00:00","items":["8.01","9.01"],"status":"ready","headline":"Adagio submits PMA to FDA for vCLAS VT ablation system; trial shows 97.4% acute success","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["PMA application for vCLAS Ventricular Ablation System to treat drug-refractory VT in structural heart disease.","FULCRUM-VT pivotal trial (209 patients, 20 centers) achieved 97.4% acute clinical success and 84.3% freedom from ICD shock at 6 months.","Major adverse events rate of 2.4%; 78% reduction or elimination of anti-arrhythmic drug use.","First-ever PMA submission for a purpose-built VT ablation system; estimated addressable market of $5.8 billion.","CEO Todd Usen states vCLAS endocardial-only approach could democratize VT ablation for electrophysiologists."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22764,"accession_number":"0001104659-26-059026","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2026-05-12T12:05:25+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adagio Medical reports Q1 2026 net loss $7.0M, cash $12.9M; FULCRUM-VT shows 84% freedom from ICD shock","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.0M for Q1 2026 vs $7.7M in Q1 2025; no revenue; R&D expense $2.7M, SG&A $2.5M.","Cash and equivalents of $12.9M as of March 31, 2026; up to $31M additional from milestone-based warrants.","FULCRUM-VT pivotal trial: 84% freedom from ICD shock at 6 months, 2.4% MAE, 72% reduction in antiarrhythmic drug use.","FDA approved IDE to expand FULCRUM-VT trial to evaluate next-generation vCLAS Ultra System.","Successfully completed 13 cases under FDA Expanded Access in patients who failed prior ablation therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97161,"accession_number":"0001104659-26-048833","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Adagio Medical reports positive pivotal vCLAS ventricular ablation trial results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["84% freedom from ICD shock and 59% freedom from VT recurrence at 6 months in FULCRUM-VT study.","2.4% protocol-defined major adverse events; 98% non-inducibility of targeted VT at end of procedure.","Equivalent outcomes for ischemic and non-ischemic cardiomyopathy patients from endocardial approach.","72% of patients discontinued or reduced amiodarone dose at 6 months; low 1.9% VT-related readmission rate.","Results from 209-patient IDE trial to support FDA Premarket Approval application for vCLAS system."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97160,"accession_number":"0001104659-26-045536","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Adagio Medical sets 2026 annual meeting for June 16; deadlines for proposals","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting date: June 16, 2026.","Record date for voting: April 24, 2026.","Deadline for Rule 14a-8 shareholder proposals: April 30, 2026.","Deadline for director nominations and Rule 14a-19 notices: April 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97159,"accession_number":"0001104659-26-040673","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2026-04-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Adagio Medical receives FDA IDE approval to study next-gen vCLAS ventricular ablation system","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA grants IDE approval to expand FULCRUM-VT trial for next-gen vCLAS ULTA Ventricular Ablation System treating SMVT.","System achieves ~ -170°C for single-freeze lesions with >50% reduction in ablation time vs prior models.","Prospective, single-arm, multi-center sub-study of up to 55 patients for scar-mediated SMVT.","Next-gen vCLAS Ultra catheter designed for improved maneuverability, shorter freeze times, and scalability.","Goal is a single versatile catheter treating full VT range via endocardial approach on established ULTA platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111709,"accession_number":"0001104659-26-035699","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adagio Medical reports FY2025 net loss $25.1M; FULCRUM-VT trial fully enrolled with 97% acute effectiveness","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $25.1M for FY2025, down from $75.0M in FY2024; Q4 net loss $3.3M vs $57.4M.","Completed enrollment of 209-patient FULCRUM-VT pivotal IDE trial; preliminary 97% acute effectiveness.","Closed private placement with gross proceeds up to $50M; upfront $19M to fund FDA submission.","Cash and equivalents $17.1M as of Dec 31, 2025; no revenue reported.","Appointed former Medtronic executive Sean Salmon to Board; added senior sales and manufacturing VPs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128345,"accession_number":"0001104659-25-121586","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Adagio Medical annual meeting elects directors Usen and Cox, ratifies auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Todd Usen elected with 12,915,589 votes for and 19,972 withheld; James L. Cox, M.D. elected with 11,610,366 for and 1,325,195 withheld.","Ratification of WithumSmith+Brown, PC as auditor approved: 13,407,336 for, 352,547 against, 102,553 abstain.","65.45% of outstanding shares present or represented; broker non-votes of 926,875 on director election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128344,"accession_number":"0001104659-25-120352","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Adagio Medical expands board to seven, appoints former Medtronic EVP Sean Salmon","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from six to seven directors; Salmon appointed Class II director, term expiring at 2026 annual meeting.","Salmon served as Medtronic EVP and President of Cardiovascular Portfolio from Jan 2021 to Sep 2025.","Appointed to Audit and Compensation Committees; will receive standard non-employee director compensation.","Company entered into standard indemnification agreement with Salmon.","No arrangements or material transactions with any other person in connection with appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128343,"accession_number":"0001104659-25-110336","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adagio Medical Q3 net loss $10.1M vs $4.6M; completes 209-patient VT trial, closes $50M placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.1M in Q3 2025, vs $4.6M in Q3 2024; cash $4.7M as of Sep 30, 2025.","Completed enrollment of 209-patient FULCRUM-VT pivotal trial for vCLAS System VT ablation; demonstrated 97% acute effectiveness.","Closed private placement on Oct 20, 2025 with gross proceeds up to $50M; upfront ~$19M to fund PMA submission.","Appointed Deborah Kaster as Chief Financial Officer, adding to her role as Chief Business Officer.","R&D expenses $2.8M; SG&A expenses $2.9M, down from $7.8M in prior year quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128342,"accession_number":"0001104659-25-102156","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Adagio Medical sets 2025 Annual Meeting for Dec 15; record Oct 31, proposal deadline Nov 3","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting will be held December 15, 2025; record date is October 31, 2025.","Stockholder proposals for inclusion in proxy materials under Rule 14a-8 due by November 3, 2025.","Director nominations and other proposals under bylaws must be received by November 3, 2025.","Universal proxy rule compliance notice required by November 3, 2025.","No 2024 Annual Meeting was held; this filing sets the new meeting and deadlines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128341,"accession_number":"0001104659-25-100727","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Adagio Medical closes $19M private placement to fund VT ablation device and FDA submission","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed $19M upfront private placement led by existing and new healthcare institutional investors.","Proceeds to support FULCRUM-VT pivotal study PMA submission for vCLAS ULTC System and next-gen catheter.","Will expand manufacturing, scale commercial-readiness, and extend cash runway into key inflection points.","Over 350 patients treated across regulatory studies, commercial, and compassionate use.","CEO states financing de-risks execution and provides flexibility to advance ULTC therapies for VT."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128340,"accession_number":"0001104659-25-099535","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Adagio Medical (ADGM) announces $19M upfront, $31M potential warrant proceeds in private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront proceeds ~$19M from 9.79M shares/pre-funded warrants at $1.9403 combined; Perceptive Advisors affiliate invests $4.25M.","Warrants (Tranche A/B/C) exercisable at $1.71/share for up to ~18M shares; expire based on FULCRUM-VT results, FDA approvals.","Proceeds used for working capital and advancement of cardiac ablation clinical and product development activities.","Private placement led by existing investor Perceptive Advisors; Piper Sandler sole placement agent; closing expected week of Oct 13."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128339,"accession_number":"0001104659-25-098701","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Adagio Medical reports 97.4% acute effectiveness in FULCRUM-VT pivotal study for VT ablation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["207 patients enrolled at 19 U.S./Canadian sites; 97.4% acute clinical success (non-inducibility of target VTs).","Major adverse event rate 2.5%; four peri-procedural deaths (1.9%), one device-related (0.5%).","Study included ICM and NICM patients (mean LVEF 35%, 75% with CHF); mean procedure time 206 min.","ULTC system uses -196°C cryoablation without irrigation; 6-month primary endpoint expected at HRS 2026.","Next-generation 8.5Fr catheter with shorter ablations in development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128338,"accession_number":"0001104659-25-095343","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Adagio completes enrollment in FULCRUM-VT pivotal IDE study for vCLAS cryoablation system","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Enrolled 208 patients across 20 U.S. and Canadian centers for vCLAS System to treat monomorphic ventricular tachycardia.","Study results support PMA application; FDA granted Breakthrough Device Designation for vCLAS.","Primary efficacy endpoint: six-month freedom from recurrent MMVT without new/increased antiarrhythmic drugs.","Company anticipates FDA PMA approval by year-end 2026, consistent with prior guidance.","vCLAS System commercially available in Europe for MMVT; limited to investigational use in the U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145145,"accession_number":"0001104659-25-088048","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Adagio Medical appoints Deborah Kaster as CFO, replacing interim CFO Dan George","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Deborah Kaster, previously CBO, becomes CFO effective September 5, 2025; Daniel George steps down as interim CFO.","Kaster's annual base salary is $366,000; eligible for bonus up to 40% of base salary and 4% raise upon equity financing of at least $5 million.","Kaster holds options to purchase 819,000 shares, with 728,000 time-based vesting over 4 years and 91,000 immediate upon change of control exceeding $250 million.","Severance: 6 months salary for qualifying termination, or 12 months plus prorated bonus if termination occurs near a change of control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145144,"accession_number":"0001558370-25-011411","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Adagio Medical Q2 2025 net loss $3.9M; FULCRUM-VT enrollment at 85%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $3.9M ($0.26 basic EPS) from $5.7M in Q2 2024; revenue figure not disclosed.","Cash and equivalents of $8.2M as of June 30; cash burn reduced via corporate prioritization.","FULCRUM-VT pivotal study enrollment surpassed 85% of 206 patients; completion expected H2 2025.","First-in-human PARALELL PFCA results published in Journal of Cardiovascular Electrophysiology.","R&D expense down 31% to $2.0M; SG&A down 29% to $2.4M year-over-year."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163543,"accession_number":"0001104659-25-049436","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adagio Medical Q1 net loss $7.7M; FDA breakthrough device designation","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.7M ($0.50 per share) vs $8.0M ($10.28 per share) in Q1 2024.","Cash and cash equivalents $13.0M as of March 31, 2025.","FDA granted Breakthrough Device Designation for vCLAS Cryoablation System for ventricular tachycardia.","FULCRUM-VT pivotal study surpassed 50% enrollment; completion on track for H2 2025.","Hired Deborah Kaster as Chief Business Officer; corporate prioritization on FULCRUM-VT trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163542,"accession_number":"0001558370-25-005261","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Adagio Medical appoints Daniel George as Interim CFO effective April 17, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel George appointed Interim CFO, principal financial and accounting officer.","Compensation set at $400 per hour; employment is at-will.","George previously served as CFO of Lucira Health and part-time CFO of Anebulo Pharmaceuticals.","No family relationships or material transactions with the company.","Offer letter to be filed with Q1 2025 Form 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163541,"accession_number":"0001104659-25-031255","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Adagio Medical reports FY2024 revenue up 101% to $0.6M, net loss widens to $75M, appoints CBO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year revenue $0.6M (+101% YoY); net loss $75.0M vs $36.6M prior year, driven by $49.2M impairment charge.","Q4 revenue $137K (+76% YoY); net loss $57.4M vs $8.6M; gross margin negative 1012%.","Cash and short-term investments $20.6M as of Dec 31, 2024.","FULCRUM-VT pivotal study enrollment over 40%; completion target H2 2025.","Appointed Deborah Kaster as Chief Business Officer, effective March 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181459,"accession_number":"0001104659-25-024408","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"CFO John Dahldorf resigns; FULCRUM-VT trial enrollment exceeds 40%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CFO John Dahldorf resigns effective March 21, 2025, no dispute over accounting; transitional CFO to be named.","FULCRUM-VT pivotal study (vCLAS catheter) enrollment over 40%, on track for full enrollment H2 2025.","Company to present ULTC data at EHRA 2025 (March 30-April 1) on scar-related VT and PVC ablation.","Streamlining focus on ventricular tachycardia solutions; CEO notes sufficient financial resources to achieve goals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181458,"accession_number":"0001104659-25-020319","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Adagio Medical COO Hakon Bergheim departs in corporate restructuring","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hakon Bergheim, Chief Operating Officer, departed effective February 28, 2025.","Departure is part of a corporate restructuring announced on February 28, 2025.","No new compensatory arrangement entered into; severance package currently being negotiated.","Material terms of any severance agreement will be disclosed via future 8-K amendment if finalized."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181457,"accession_number":"0001104659-25-018724","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Adagio Medical restructures to focus on US pivotal IDE trial; reduces workforce","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pauses limited European launch of vCLAS catheter; redirects resources to US FULCRUM-VT Pivotal IDE trial (over 35% enrolled).","Reduction in force effective February 28, 2025, to enable additional investment in clinical trial and product design optimization.","Streamlining operations and realigning resources toward US FDA premarket approval for VT Cryoablation System with vCLAS catheter.","CEO Todd Usen cites broad applicability of ultra-low temperature cryoablation technology and aim to lead ventricular tachycardia market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181456,"accession_number":"0001104659-25-009533","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Adagio Medical terminates Facilities and Services Agreement with Fjord Ventures, effective July 30, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Notice of termination sent Jan 30, 2025; agreement terminates July 30, 2025 (180 days from Jan 31).","Agreement covered employee benefits admin, IT, office space; company no longer needs these services.","Company also had sub-lease of ~4,992 sq ft in Laguna Hills, CA, which expired March 31, 2024.","Company expressed willingness to negotiate new agreement with Fjord for ongoing needs post-termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181455,"accession_number":"0001104659-25-001387","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["1.01","3.01","9.01"],"status":"ready","headline":"Adagio Medical enters waiver for defaults, receives Nasdaq non-compliance letter","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Issued 183,333 restricted shares at $2.00 per share to settle registration delay payments with buyers.","Buyers waived defaults including misstated financials that caused delayed payments and lapsed registration.","Received Nasdaq notice for audit committee vacancy after Shahram Moaddeb's resignation; cure period until Jan 2, 2026.","Company must file a new registration statement by February 28, 2025 per waiver terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198256,"accession_number":"0001558370-24-016460","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"Director resigns; Adagio Medical to be non-compliant with Nasdaq audit committee rule","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shahram Moaddeb resigns as director effective Jan 1, 2025, citing demands of other business ventures; no dispute with company.","Resignation leaves audit committee with a vacancy, triggering non-compliance with Nasdaq Listing Rule 5605(c)(2)(A) as of Jan 1, 2025.","Company notified Nasdaq on Dec 20, 2024 of expected non-compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198255,"accession_number":"0001558370-24-016265","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Adagio Medical appoints Todd Usen as CEO; founder Olav Bergheim departs as CEO and Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Olav Bergheim resigns as CEO and Chairman effective Dec 13, 2024; receives severance of $1.2M cash plus contingent $300K.","Bergheim will serve as advisor for 12 months and receives an option for 338,398 shares of common stock.","Todd Usen appointed CEO and Director effective Dec 13, 2024; base salary $500K/year, bonus up to 50%, and option for ~5% fully diluted shares.","Orly Mishan appointed Chairperson of the Board effective Dec 13, 2024.","Bergheim's departure not due to disagreement with financial reporting or operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198254,"accession_number":"0001558370-24-015702","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adagio Medical Q3 2024 revenue $185K (+351% YoY); net loss $4.6M; CMS coverage secured","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $185K in Q3 2024, up 351% from $41K in Q3 2023.","Net loss of $4.6M improved from $10.8M in Q3 2023; driven by fair value changes on convertible notes.","Cash and short-term investments of $28.3M as of September 30, 2024.","CMS Category B coverage secured for vCLAS catheter in FULCRUM-VT IDE study for drug-resistant VT.","First procedures performed in FULCRUM-VT pivotal study; 206 patients at 20 US/Canadian centers to support FDA PMA."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":132000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198252,"accession_number":"0001558370-24-014189","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K/A","filed_at":"2024-11-04T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Adagio Medical restates FY2023 financials due to duplicate interest accounting; net loss reduced by $1.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Restatement corrects double-counting of accrued interest on convertible notes; net loss for 2023 reduced by $1.556M to $36.590M.","Convertible notes payable reduced by $1.556M to $36.430M as of Dec 31, 2023; accumulated deficit revised to $133.649M.","Auditor's report includes going concern doubt: $1.4M cash on hand, $133.6M accumulated deficit, recurring losses.","Company completed SPAC merger with ARYA on July 31, 2024; filing restates legacy financials for periods before that transaction.","Net cash used in operations was $25.7M for 2023; working capital deficit of $42.0M as of Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198253,"accession_number":"0001558370-24-014144","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Adagio Medical announces restatement of FY2023, Q1 and Q2 2024 financials; material weakness identified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee concluded FY2023 audited and Q1/Q2 2024 unaudited statements should not be relied upon due to accrued interest misstatement.","Error found during Q3 2024 prep; overstatement of accrued interest on convertible notes and other liabilities.","Company will restate financials via Amendment No. 2 to the Business Combination Super 8-K.","Material weakness in internal control over financial reporting regarding review of third-party valuation reports for debt/equity.","Remediation plan includes additional review of valuation reports, manual journal entries, and enhanced oversight controls."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214378,"accession_number":"0001104659-24-090842","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Adagio Medical obtains CE Mark for VT catheter, closes business combination with $35M pro forma cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CE Mark approval and commercial launch of vCLAS catheter for ventricular tachycardia in select European markets.","FDA approved FULCRUM-VT pivotal IDE study for VT cryoablation system; patient enrollment starts September 2024.","Closed business combination with ARYA Sciences Acquisition Corp; shares listed on Nasdaq under ADGM on Aug 1, 2024.","Raised approx. $84.2M from trust, PIPE, and convertible financing; pro forma cash ~$35M after transaction costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214376,"accession_number":"0001140361-24-037365","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K/A","filed_at":"2024-08-14T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Adagio Medical closes SPAC merger with $84.2M in financing; reports H1 2024 net loss of $14.5M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Business combination with ARYA Sciences Acquisition Corp IV closed on July 31, 2024, providing ~$84.2 million in financing.","Transaction costs corrected to ~$13.1 million, including $1M payoff of SVB Term Loan.","Adagio Medical's H1 2024 revenue $280,000; net loss $14.5 million; cash $2.0 million as of June 30, 2024.","Working capital deficit of $58.0 million at June 30, 2024; going concern doubt alleviated by merger closing.","Adagio issued $15.5 million in convertible notes during H1 2024; converted 207,902 preferred shares for pre-funded warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214377,"accession_number":"0001140361-24-035942","cik":2006986,"company_name":"Adagio Medical Holdings, Inc.","ticker":"ADGM","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["1.01","2.01","3.02","9.01","3.03","5.03","5.01","5.02","5.05","5.06","7.01"],"status":"ready","headline":"Adagio Medical completes de-SPAC merger with ARYA, begins trading as ADGM on Nasdaq","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Post-combination, 13,387,636 shares of New Adagio common stock outstanding; 7,587 shares under options.","PIPE financing of ~$64.5M closed; $20M in 13% senior secured convertible notes issued with 1,500,000 warrants exercisable at $24/share.","Sponsor forfeited 1,000,000 Class B shares; additional 1,147,500 shares subject to vesting if stock reaches $24 for 20 trading days.","Shareholders redeemed 2,707,555 shares for ~$31.3M at ~$11.56 per share prior to closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":15702794.11818182,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}